Israel-based Teva Pharmaceutical Industries has reported positive results from a Phase IIb trial of two doses of subcutaneous TEV-48125, an investigational anti-calcitonin gene-related peptide (CGRP) monoclonal antibody for the prevention of chronic migraine.
Subscribe to our email newsletter
The trial evaluated the efficacy, safety, tolerability as well as compared two active arms of different doses of TEV-48125, administered as a subcutaneous injection, once a month for three months, against placebo.
The results showed that both tested doses of TEV-48125 achieved the trial’s primary and secondary efficacy endpoints one and three months.
Teva head of Global Clinical Development for Migraine and Headaches Marcelo Bigal said: "For the first time in chronic migraine, there is clinical data on the positive role of calcitonin gene-related peptide signaling disruption using a monoclonal antibody."
Teva president of global R&D and chief scientific officer Michael Hayden said: "Chronic migraine is a challenging, complex and highly debilitating condition that desperately needs effective new treatment options.
"These results in support of TEV-48125 take us a step closer to realizing the potential of the anti-CGRP ligand-based approach for millions of women and men who suffer from chronic migraine."
After a 28 day run-in period in trial, qualifying patients were randomized to one of three treatment arms receiving high dose TEV-48125, low dose TEV-48125 or placebo, given subcutaneously once a month for three months.
A total of 261 patients were included in the multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel group, multi-dose trial, of which 172 received TEV-48125.
The company said that full results from the trial will be presented at a forthcoming meeting and will be submitted to a peer-reviewed journal for publication.